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Abstract Non-alcoholic fatty liver disease (NAFLD) is large-
ly linked to poor diet, lack of physical activity/exercise, and
being overweight. In the absence of approved pharmaceutical
agents, lifestyle modification, encompassing dietary change
and increased physical activity/exercise to initiate weight loss,
is the recommended therapy for NAFLD. Despite this, the use
of lifestyle therapy within clinical settings is lacking with lim-
ited guidance available about what it should involve, how it
should be delivered, and whether it can be feasibly delivered
as part of standard care. This paper highlights the evidence for
the use of lifestyle modification in NAFLD. While there is
evidence to support use of behavioral strategies to support
lifestyle behavior change in other clinical populations, these
are yet to be assessed in people with NAFLD. However, there
is sufficient evidence to suggest that behavioral intervention
targeting diet and physical activity to promote weight loss in
general is effective and a number of practical strategies are
presented on how this could be achieved.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is rapidly becom-
ing the most common liver condition in the world and is
largely linked to increased calorie consumption/poor diet, lack
of physical activity/exercise, and being overweight. NAFLD
represents a spectrum of liver disease ranging from isolated
fatty liver to progressive non-alcoholic steatohepatitis
(NASH), hepatic fibrosis, and cirrhosis. The overall preva-
lence of NAFLD in adults in Western countries is estimated
to be 20–33 % [1, 2], and incidence increases in people with
obesity and type 2 diabetes (T2DM). Patients with simple
fatty liver have a relatively Bbenign^ liver prognosis with a
1–2 % risk of developing evidence of cirrhosis over 15–
20 years [3], while up to 5–11 % of those with NASH develop
end-stage liver disease [4•]. Furthermore, excess liver fat
markedly increases cardiovascular disease risk, and heart dis-
ease is the second most common cause of death in those with
NAFLD [5].
In the absence of approved pharmaceutical agents, lifestyle
modification, involving weight loss, initiated by dietary and
physical activity/exercise behavior change, is the primary rec-
ommended therapy for NAFLD [6]. Despite this, the use of
lifestyle therapies in the clinical setting is severely lacking
with limited guidance about how this should be delivered
and what should be included as part of standard care. The
American Association for the Study of Liver Disease pub-
lished practice guidelines in 2012 regarding the diagnosis
and management of NAFLD [7]; however, these were vague,
particularly with regard to targeting lifestyle behavior change
as a treatment modality for NAFLD. The Lancet Standing
Commission [8] recommends the promotion of healthy life-
styles to address the current obesity epidemic in the fight
against NAFLD but again fails to provide specific details as
to how this should or could be achieved.
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Evidence supporting the use of lifestyle therapy is strong
and has shown significant reductions in liver fat and improve-
ments in glucose control/insulin sensitivity in those with
NAFLD after short dietary and exercise interventions [9•].
The majority of research assessing the effect of lifestyle mod-
ification on NAFLD has been in the early stages of the disease
(i.e., in people with simple steatosis) rather than the later
stages. Lifestyle interventions designed to induce weight loss
through reduced energy intake (dietary behavior change only)
in NAFLD have led to reductions in liver fat of 42–81 %
[10–12] with the greatest reductions in liver fat observed in
people who lose the most weight. Weight loss has also dem-
onstrated to be successful in treating NASH, again with a
greater weight reduction associated with better improvements
in histology on repeat biopsy [13]. However, weight loss is
difficult to achieve in the clinical setting, and weight loss
maintenance poses a significant challenge; thus, an alternative
approach is required. A few small-scale studies have investi-
gated the effect of exercise alone (without weight loss or die-
tary change) in NAFLD. These studies have consistently
shown a reduction in liver fat of 12–27 % and/or improve-
ments in liver enzymes following short programs of traditional
aerobic [14, 15], modified high-intensity interval training
[16], or resistance exercise [17]. Studies investigating the
combined effects of diet and exercise in NAFLD have report-
ed reductions in liver fat of 23–51 % [18, 19], and one study
reported significant changes in NAFLD histology on repeat
biopsy [20]. These studies provide support for the use of life-
style modification incorporating diet and exercise, with
weight loss offering the largest improvements for liver health.
A weight loss goal of circa 10 % has been recommended
for patients with NAFLD [13, 21, 22]; however, weight loss is
difficult to achieve and sustain even in well-conducted and
resourced clinical trials. If patients can lose a small amount
of weight through diet and/or exercise, they can reduce their
risk of disease progression and worsening metabolic control
[9]. Patients electing to exercise who remain weight neutral
can benefit from an improvement in body composition with an
increase in lean-mass to fat-mass ratio and thus have a greater
fat burning capacity and less fatty tissue despite lack of weight
loss [6, 7]. Weight loss is a key in NAFLD; however, if a
patient is unable to lose weight via dietary behavior change
alone, physical activity and exercise offer an alternative route
to improving liver and metabolic health.
Public health guidelines recommend that adults undertake a
minimum of 150 min/week of moderate-vigorous leisure-time
physical activity to decrease risk of metabolic disease [23, 24].
However, the majority of people in the general population do
not strive for or achieve this recommendation, and this is like-
ly contributing to increased prevalence of obesity, T2DM, and
NAFLD. Low levels of physical activity are associated with
an increased risk of developing chronic diseases, including
cardiovascular disease [25], T2DM [26, 27], and cancer
[28]. Interventions that increase physical activity have shown
to be effective in the prevention of these diseases [29–33] but
have yet to be assessed in NAFLD. Research has shown that
objectively measured levels of physical activity behavior are
lower in people with NAFLD than in matched healthy con-
trols and that people with NAFLD are more sedentary [34•].
Furthermore, physical activity levels are inversely related to
liver fat [35], and as such people with NAFLD should be
encouraged to increase their physical activity levels. This
may be in the form of increasing day-to-day physical activity
(e.g., walking) or by taking part in structured exercise
programs.
Key Points from Recent Dietary Studies
Studies investigating dietary composition have been largely
inconclusive regarding which type of diet is the most effective
for managing NAFLD [9•, 21, 36]. The key findings point
towards calorie reduction as being the most important factor
in facilitating weight loss regardless of the type of diet a per-
son consumes. Low calorie diets and very low calorie diets
(including meal replacement products) are effective for induc-
ing rapid weight loss [36]; however, patients are likely to
require a greater level of support to adhere to these diets and
would require close monitoring, particularly if they have dia-
betes. Diets enriched with fructose, trans-fatty acids and satu-
rated fat (i.e., the typical western diet) have shown associa-
tions with the development of NAFLD [37, 38]. Therefore,
restricting calories from these common sources may be impor-
tant, particularly considering higher fructose consumption has
also been associated with an increase in fibrosis severity in
patients with NAFLD [39]. For long-term weight loss main-
tenance, a general healthy balanced diet is recommended [6],
although patients will also require specific personalized infor-
mation about energy intake and expenditure as well as support
to better self-regulate their diet and physical activity levels.
Key Points fromRecent Physical Activity/Exercise Studies
Patients with NAFLD have been shown to undertake lower
levels of physical activity and are more sedentary than their
healthy counterparts [34•, 40]. Increasing physical activity
levels and reducing sedentary time not only increases energy
expenditure, thus enhancing weight loss, but also has benefi-
cial effects on metabolic and cardiac risks [16, 41]. Exercise
studies have shown improvements in NAFLD in the absence
of weight loss and evidence supports different types (aerobic,
resistance and high-intensity interval training [12–16]) and
doses of exercise as being effective [42•, 43]. This is good
news for patients because it provides the necessary evidence
that any form of exercise is likely to be beneficial and so
provides patient choice. There is strong evidence to support
the use of pedometers and activity trackers to provide
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estimation of baseline activity levels and for use as motiva-
tional and volitional tools to increase physical activity behav-
ior and improve health [44]. Central to physical activity/
exercise promotion is supporting patients to make an initial
step towards increasing their physical activity levels. This in-
volves assisting them to identify salient reasons for making a
change to physical activity levels, selecting an activity of
choice, advising them on the necessary amount of activity
required to attain a pre-set end goal (e.g., reduced liver fat),
providing feedback on performance in relation to clinical out-
comes, and providing ongoing support to prevent relapse. The
need for patients to find an activity they enjoy is paramount to
increase the likelihood of long-term sustainable changes.
Supporting patients to identify ways in which they can in-
crease their everyday level of physical activity or helping them
to locate exercise schemes in the community can be useful to
support this.
Clinical Observations: Targeting Lifestyle Behavior
Change of Adults with NAFLD
Typically, patients with NAFLD present to clinicians as over-
weight or obese with a host of co-morbidities likely to include
overt T2DM and/or CVD or risk factors for the development
of both diseases. Patients are largely inactive and report diffi-
culty losing weight and maintaining weight loss. The chal-
lenge with these patients is to motivate them to want to make
long-term changes to their lifestyle behaviors and to support
them to make changes that will result in weight loss and
weight loss maintenance and thus benefit their liver, metabol-
ic, and cardiac health [9]. Clinical care needs to be Bpatient-
centered^ with less of a didactic approach to the consultation
and more of a two-way conversation where the clinician at-
tempts to understand the patients’ previous experiences with a
view to moving forward with treatment.
The first challenge is to ensure that patients understand
their diagnosis: what NAFLD is, why they have developed
it, and what they can do to halt disease progression or reverse
their condition. It is also important from the outset to explain
to the patient that their liver disease is linked to lifestyle be-
haviors (i.e., diet and physical activity levels) and excess
weight as opposed to alcohol consumption in the majority of
cases. Many patients link liver disease solely to excess drink-
ing, and this can be a significant barrier to acceptance of their
diagnosis, particularly if their alcohol consumption is within
the recommended limits. This can create difficulties when
trying to move a patient forward with treatment.
Traditionally, patients with NAFLD are told/advised by clini-
cians to lose weight; however, commonly, they are not sup-
ported to make any meaningful changes to their lifestyle be-
haviors. This frequently results in unsuccessful weight loss
attempts and disengagement with services. Often, these are
people that have tried (and failed) a multitude of different diets
over several years and have received conflicting information
from health-care professionals, friends, family members, and
the media, which has resulted in confusion as to what the
correct advice is.
To promote successful lifestyle behavior change, greater
emphasis is being placed on the use of evidence-informed
behavior change techniques [45] and/or brief motivational
techniques [46] for use within clinical settings. These tech-
niques are used to increase motivation (i.e., address common
misconceptions, identify personal reasons for change and
ways in which patients can successfully change their lifestyle
behaviors to increase intention) and support volition (i.e., pro-
motion of practical strategies that patients can use such as goal
setting and barrier identification to plan behavioral changes
and maintain changes over time) [47•, 48–50]. Previous expe-
riences of successful/unsuccessful lifestyle behavior changes
can be explored to identify what worked well so that these
experiences can be utilized to inform future behavioral change
strategies.
At the start of the management process, it is important to
determine what a patient already knows about NAFLD, why
they believe they have developed the disease, and whether
they have been advised of ways in which they can manage it
(i.e., the very first consultation may involve addressing mis-
conceptions, however by providing patients with the correct
information; this in itself can raise self-efficacy and make
lifestyle behavior change more likely). Once it has been
established that the patient is ready and willing to proceed
with lifestyle behavior changes, it is important to explore
and understand their current diet and eating habits, for exam-
ple, what type of foods do they eat, the size of their portions,
learning who does the cooking/food shopping in the house-
hold, have they already started to think about or make any
changes, and have these been successful? It may be useful
for the patient to use a food diary to record their current dietary
intake in detail. This not only gives a baseline measure to
facilitate feedback provision but can also be used to identify
any patterns in behavior, track any future changes, and pro-
vides a good opportunity to start a discussion around making
changes to the diet. If a patient is unable to provide a good
indicator of their portion sizes of different food types, they can
take a photograph of their meal on their plate that will help to
Bvisually quantify^ how much they are eating. Most patients
will need to reduce their portion sizes of some, if not all, food
types and buying a smaller plate on which to eat their meals is
often a good way of doing this without their Bnormal^ plate
appearing empty. As discussed previously, the evidence does
not support a particular type of diet for weight loss in NAFLD;
the emphasis currently is on the reduction of calorie
consumption.
Physical activity and exercise are often overlooked during
the clinical consultation in patients with NAFLD. This is de-
spite evidence showing the positive benefits on liver,
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metabolic, and cardiac health. It is beneficial to obtain a base-
line measure of physical activity for each patient, including
the types of activities they engage with to better understand
their capabilities and the intensity at which they are working
at. This can be completed via an activity diary or ideally using
an objective measure which captures all incidental and
planned activity over a 7-day period. Pedometers are a rela-
tively inexpensive tool to capture step-count throughout the
day but do not provide any information on activity duration,
intensity, or non-stepping activities. Furthermore, they do not
provide any context or information about the actual activities
undertaken. Activity monitors can provide added information
with regard to energy expenditure, frequency, duration, and
intensity of activities performed and data on daily activity
profile that is useful to target sedentary behavior. These mon-
itors are more expensive and are mainly used for research
purposes; however, with the increased use of smart phones,
patients can often use Apps to track their activity in a more
sophisticated way than using a traditional pedometer. Some
Apps will use global positioning system (GPS) technology
and allow a patient to track their walking, not only in terms
of step count but also distance and speed. Having an objective
measure of baseline activity levels allows clinicians to work
with patients to set appropriate and realistic goals. For exam-
ple, if a patient is currently achieving 2000 steps per day, it is
unlikely that they will reach the recommended target of 10,
000 steps per day [23] immediately; therefore, graded behav-
ioral goal setting may be more appropriate, although this
should be explored and discussed with the patient (i.e., an
assumption should not be made). Supporting patients to set
walking goals may be an appropriate starting point to increase
their physical activity levels as opposed to a structured exer-
cise program. Conversely, someone that has co-morbidities
that restrict their walking may benefit from sign-posting to a
swimming group or chair-based exercise program. The key to
long-term success in supporting patients to increase their
physical activity/exercise levels is to establish what motivates
them to make lifestyle behavior changes and what types of
activities are in line with their capabilities and preferences.
Once this is established, patients can be sign-posted to activ-
ities of their choice or link with other services that may offer
these opportunities. To facilitate such a process, it is beneficial
to have an up-to-date list of local physical activity/exercise
providers to ensure the information is available at a time when
the patient requests it (i.e., at a time where they are motivated
or a key teachable moment). Maintaining close relationships
with local leisure service teams can prove invaluable as they
can help to support patients with NAFLD to make and sustain
these lifestyle behavior changes.
As referred to previously, people with NAFLD rarely re-
ceive support to make meaningful and sustainable changes to
diet and physical activity behavior. This is potentially due to a
number of factors including lack of knowledge and awareness
on the part of the clinician of the importance of lifestyle factors
in the context of NAFLD. However, the most significant fac-
tor is likely to be a lack of training in the delivery of behavior
change interventions (i.e., use of behavior change and brief
motivational techniques). When targeting lifestyle behavior
change, we can typically think of the process occurring in
three stages. The first involves determining whether the pa-
tient regards changing their diet and/or physical activity be-
havior as important (i.e., whether they believe changing be-
havior will make a difference) and whether they feel confident
that they can make changes that will make a difference (i.e.,
whether they feel practically equipped to make changes and
whether self-efficacy is high). If importance and confidence
levels are high, then the patient is likely to feel motivated to
move forward and make goals and plans. If not, the clinician
should work with the patient to explore attitudes, beliefs, and
self-efficacy first to increase the importance of making life-
style behavior changes and to enhance self-efficacy. The sec-
ond stage involves working with patients to make realistic
goals and detailed plans that they feel are sustainable and
sensitive to their everyday lives. These goals and plans should
be capable of initiating a change in the target behavior(s) if
they have been developed in collaboration with the patient.
Self-monitoring at this stage can help to self-regulate lifestyle
behaviors and increases self-efficacy when the patient starts to
attain their goals. The final stage involves equipping patients
with practical strategies such as methods to pre-plan ways to
overcome barriers to prevent relapse and self-monitoring be-
havior to positively reinforce any changes made (i.e., increase
self-efficacy). See Fig. 1.
There are a range of behavior change techniques and be-
havior change counseling techniques available for use, some
with a stronger evidence base than others for targeting each
stage in the process. For example, use of self-regulatory tech-
niques such as self-monitoring has a good evidence base, and
when paired with problem-solving and coping planning is
regularly effective for changing physical activity behavior
[51, 52]. However, there is currently a pressing need for train-
ing provision in health behavior change for clinicians to target
lifestyle behaviors in the context of NAFLD.
Conclusions
Targeting lifestyle modification in people with NAFLD is vi-
tally important, not only due to the high disease prevalence but
also since excess liver fat is an independent risk factor for the
development of cardiovascular disease and T2DM. Reducing
liver fat and its mediators should be beneficial for delaying or
preventing the onset of these life-threatening conditions,
which in turn reduces the burden placed on health services.
Clinicians are inevitably going to be managing increasing
numbers of patients with NAFLD in the future, and it is
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important for them to have the ability and capacity within
health-care settings to motivate and support patients to make
lifestyle behavior changes that can be sustained over the long
term. This will require a change in the way that lifestyle inter-
ventions are delivered in the clinic, placing more emphasis on
the use of behavior change strategies and engaging patients in
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Fig. 1 Flow diagram outlining the process for targeting lifestyle behavior change during NAFLD consultations
a discussion about the choices they have in relation to their
care as opposed to clinicians providing unsolicited advice.
This is achievable; however, evidence-based tools and train-
ing are lacking and lifestyle behavior change interventions are
likely to be a more effective solution if delivered by a multi-
disciplinary team.
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